Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MQX-503 Dose Response in Raynaud's Phenomenon
NCT00480753Phase 2
Key facts
- Status
- Completed
- Start
- May 2007
- Countries
- 1
- Sponsor
- MediQuest Therapeutics
- Modality
- Small Molecules
- Drugs
- nitroglycerin
- Conditions
- Raynaud's phenomenon (RP)
01
Overview
Phase 2, randomised, double-blind trial of nitroglycerin in Raynaud's phenomenon (RP) (3 arms), sponsored by MediQuest Therapeutics. Primary endpoint: Changes in blood flow in the fingers of the non-dominant hand at 130 minutes. Started May 2007; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
MQX-503 0.5%
Topical nitroglycerin gel 0.5%
MQX-503 1.25%
Topical nitroglycerin gel 1.25%
Placebo
Placebo gel
03
Endpoints
Primary
Changes in blood flow in the fingers of the non-dominant hand
Secondary
Reduction in skin temperature recovery time
Symptoms of pain, tingling and numbness
Frequency and severity of adverse events
Beyond the preview
Go deeper on NCT00480753.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480753.